Spin-out companies

The vision of the BDI is to translate innovative, interdisciplinary biotechnology and biomedicine advances into products and processes that improve quality and security of life. Fostering an environment that encourages commercial spin-outs and attracts spin-ins is part of our critical path. Past and present companies involving our research within the BDI reflect our core research themes.

 

Carbon capture and combatting climate change

Deep Branch: A proprietary carbon dioxide-to-protein process directly utilises CO₂ from industrial emissions to generate single-cell proteins optimised for animal feed and nutrition, thereby converting a greenhouse gas into a useful product.

 

Regeneration

Locate Bio: This world-leading, diversified orthobiologics company is focused on providing surgeons with a choice of best-in-class products.

 

Therapeutic delivery of materials, molecules or proteins

CHAINbiotech: The clostridium-assisted drug development platform combines precision engineering with a superior host bacterium to effectively deliver therapeutic payloads to the lower gastrointestinal tract.

Exonate: By modifying gene splicing machinery, this biopharmaceutical company is developing eyedrop treatment for age-related macular degeneration to transform the lives of those suffering from vision loss.

 

Vaccine development

Phenotypeca: Hosting the world's largest collection of yeast strains engineered for industrial recombinant protein production, this biotech company develops vaccines, diagnostics and therapeutic proteins.

Scancell: A well-established listed company developing innovative therapeutics, including cancer vaccines for metastatic melanoma (performing well in clinical trials) and Covid-19 (entering clinical trials).